Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wang Yuan

Showing results (141-150 of 150) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 150 results.
BMC Biology|April 13, 2019
Derivation of adult canine intestinal organoids for translational research in gastroenterologyLawrance Chandra, Dana C Borcherding, Dawn Kingsbury, et al.
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi = Chinese Journal of Schistosomiasis Control|January 16, 2016
[Evaluation on molluscicidal effect of chlorosalicylicamide on Oncomelania hupensis in schistosomiaisis endemic areas of eight provinces in China]Feng-hua Wei, Xing-jian Xu, Yi Yuan, et al.
Cancer Cell|April 18, 2025
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiationMona Teng, Jiacheng Guo, Xin Xu, et al.
Alimentary Pharmacology & Therapeutics|March 31, 2026
Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2311)Rong Ding, Jin-Feng Bai, Zhi-Cheng Jin, et al.
Nature Genetics|March 25, 2025
The landscape of N<sup>6</sup>-methyladenosine in localized primary prostate cancerXin Xu, Helen Zhu, Rupert Hugh-White, et al.
Hepatology (Baltimore, Md.)|November 10, 2025
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204)Zhi-Cheng Jin, Jingwei Wei, Yu-Dong Xiao, et al.
Journal of Cachexia, Sarcopenia and Muscle|November 27, 2024
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213)Zhi-Cheng Jin, Jia-Wei Zhou, Jian-Jian Chen, et al.
Eclinicalmedicine|May 15, 2024
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation studyZhi-Cheng Jin, Jian-Jian Chen, Xiao-Li Zhu, et al.
Aging Medicine (Milton (N.S.W))|July 7, 2025
Chinese Expert Consensus on Standardized Outpatient Management of Sarcopenia in the Elderly (2024)Zhang Qin, Kang Lin, Wang Jianye, et al.
Signal Transduction and Targeted Therapy|February 8, 2023
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)Hai-Dong Zhu, Hai-Liang Li, Ming-Sheng Huang, et al.
Pageof 15

Showing results (141-150 of 150) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
BMC Biology|April 13, 2019
Derivation of adult canine intestinal organoids for translational research in gastroenterologyLawrance Chandra, Dana C Borcherding, Dawn Kingsbury, et al.
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi = Chinese Journal of Schistosomiasis Control|January 16, 2016
[Evaluation on molluscicidal effect of chlorosalicylicamide on Oncomelania hupensis in schistosomiaisis endemic areas of eight provinces in China]Feng-hua Wei, Xing-jian Xu, Yi Yuan, et al.
Cancer Cell|April 18, 2025
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiationMona Teng, Jiacheng Guo, Xin Xu, et al.
Alimentary Pharmacology & Therapeutics|March 31, 2026
Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2311)Rong Ding, Jin-Feng Bai, Zhi-Cheng Jin, et al.
Nature Genetics|March 25, 2025
The landscape of N<sup>6</sup>-methyladenosine in localized primary prostate cancerXin Xu, Helen Zhu, Rupert Hugh-White, et al.
Hepatology (Baltimore, Md.)|November 10, 2025
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204)Zhi-Cheng Jin, Jingwei Wei, Yu-Dong Xiao, et al.
Journal of Cachexia, Sarcopenia and Muscle|November 27, 2024
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213)Zhi-Cheng Jin, Jia-Wei Zhou, Jian-Jian Chen, et al.
Eclinicalmedicine|May 15, 2024
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation studyZhi-Cheng Jin, Jian-Jian Chen, Xiao-Li Zhu, et al.
Aging Medicine (Milton (N.S.W))|July 7, 2025
Chinese Expert Consensus on Standardized Outpatient Management of Sarcopenia in the Elderly (2024)Zhang Qin, Kang Lin, Wang Jianye, et al.
Signal Transduction and Targeted Therapy|February 8, 2023
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)Hai-Dong Zhu, Hai-Liang Li, Ming-Sheng Huang, et al.
Pageof 15